Brief: Anebulo Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating ANEB-001 For The Treatment Of Acute Cannabinoid Intoxication
03/01/2022 12:22
Jan 3 (Reuters) - Anebulo Pharmaceuticals Inc ANEB.O :
* ANEBULO PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2
CLINICAL
STUDY EVALUATING ANEB-001 FOR THE TREATMENT OF ACUTE CANNABINOID
INTOXICATION
* ANEBULO PHARMACEUTICALS INC - AFFIRMS EXPECTATIONS FOR
INITIAL
TOPLINE RESULTS IN 1H 2022
* ANEBULO PHARMACEUTICALS INC - COMPANY EXPECTS TO SUBMIT
IND IN
1Q 2022 FOR ANEB-001
Source text for Eikon: ID:nBw4NVvyXa
Further company coverage: ANEB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Anebulo Pharmaceuticals
See all newsAdvisory: Dated alert on Anebulo Pharmaceuticals' voluntary delisting from Nasdaq withdrawn
Anebulo Pharmaceuticals Q2 net loss narrows
Brief: Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC
Anebulo Pharmaceuticals posts Q1 net loss
Brief: Anebulo Pharmaceuticals Reports Fourth Quarter And Fiscal Year 2025 Financial Results